Kaleido Z Score
KLDO   USA Stock  USD 5.82 0.15 2.65% 
Kaleido Z Score Analysis
Kaleido Biosciences' ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..2019  2020  2021 (projected)  
Invested Capital Average  13.99 M  20.88 M  20 M 
Invested Capital  18.79 M  15.31 M  16.41 M 
Z Score  =  Sum Of   5 Factors 
Current Kaleido Biosciences Z Score  3.8 
Most of Kaleido Biosciences' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kaleido Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

Kaleido Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Kaleido Biosciences is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Kaleido Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kaleido Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kaleido Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
Based on the company's disclosures, Kaleido Biosciences has a Z Score of 3.8. This is 43.7% lower than that of the Healthcare sector and 13.77% higher than that of the Biotechnology industry. The z score for all United States stocks is 56.42% higher than that of the company.
Kaleido Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kaleido Biosciences' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kaleido Biosciences could also be used in its relative valuation, which is a method of valuing Kaleido Biosciences by comparing valuation metrics of similar companies.Kaleido Biosciences is currently under evaluation in z score category among related companies.
Kaleido Fundamentals
Return On Equity  (161.51) %  
Return On Asset  (59.77) %  
Current Valuation  226.04 M  
Shares Outstanding  42.52 M  
Shares Owned by Insiders  3.91 %  
Shares Owned by Institutions  80.88 %  
Number of Shares Shorted  3.38 M  
Price to Earning  (1.45) X  
Price to Book  3.36 X  
Price to Sales  189.53 X  
Revenue  1.27 M  
Gross Profit  (54.99 M)  
EBITDA  (80.14 M)  
Net Income  (85.11 M)  
Cash and Equivalents  92.36 M  
Cash per Share  2.17 X  
Total Debt  21.19 M  
Debt to Equity  0.29 %  
Current Ratio  7.38 X  
Book Value Per Share  1.69 X  
Cash Flow from Operations  (67.59 M)  
Short Ratio  21.05 X  
Earnings Per Share  (2.38) X  
Number of Employees  82  
Beta  0.32  
Market Capitalization  241.08 M  
Total Asset  81.6 M  
Retained Earnings  (197.63 M)  
Working Capital  62.54 M  
Current Asset  72.93 M  
Current Liabilities  10.39 M  
Z Score  3.8 
About Kaleido Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kaleido Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kaleido Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kaleido Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Kaleido Biosciences, Inc., a clinicalstage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
Kaleido Biosciences Investors Sentiment
The influence of Kaleido Biosciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decisionmaking process regarding taking a position in Kaleido. The overall investor sentiment generally increases the direction of a stock movement in a oneyear investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Please see Kaleido Biosciences Piotroski F Score and Kaleido Biosciences Valuation analysis. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Kaleido Stock analysis
When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Performance AnalysisCheck effects of meanvariance optimization against your current asset allocation  Go  
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on selflearning algorithm to remember stocks you like  Go  
Watchlist OptimizationOptimize watchlists to build efficient portfolio or rebalance existing positions based on meanvariance optimization algorithm  Go  
Fundamental AnalysisView fundamental data based on most recent published financial statements  Go  
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and roboadvisors.  Go  
Global CorrelationsFind global opportunities by holding instruments from different markets  Go  
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing  Go  
Equity SearchSearch for activelly traded equities including funds and ETFs from over 30 global markets  Go  
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity  Go  
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios  Go  
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges  Go  
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings  Go  
Idea OptimizerUse advanced portfolio builder with precomputed micro ideas to build optimal portfolio  Go 
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.